Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that MET Exon 14 (Splice Site) status confers therapeutic sensitivity to Tepotinib in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved tepotinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
This statement is based on a regulatory approval from the Health Service Executive:
As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-08-01 | Health Service Executive | Indication approved for reimbursement. |
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |